Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Assembly Biosciences Inc ASMB

Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Company’s pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle... see more

Recent & Breaking News (NDAQ:ASMB)

Preclinical Data from Assembly Biosciences' Immuno-Oncology Microbiome Program Featured at AACR's Virtual Annual Meeting II

GlobeNewswire June 22, 2020

Assembly Biosciences Regains Worldwide Rights to Microbiome Gastrointestinal Development Programs

GlobeNewswire June 18, 2020

Assembly Biosciences Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 1, 2020

Assembly Biosciences Announces Management Transition

GlobeNewswire May 27, 2020

Assembly Biosciences to Present During the Jefferies Virtual Healthcare Conference

GlobeNewswire May 26, 2020

Assembly Biosciences Announces Move to Virtual-Only Annual Meeting of Stockholders on June 11, 2020

GlobeNewswire May 19, 2020

Assembly Biosciences Reports Updates on Corporate Progress and First Quarter 2020 Financial Results

GlobeNewswire May 7, 2020

Preclinical Data from Assembly Biosciences' Microbiome Program in Ulcerative Colitis Featured in DDW 2020 Virtual Meeting Portal and Upcoming Journal Supplements

GlobeNewswire May 4, 2020

Assembly Biosciences Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 1, 2020

Assembly Biosciences to Host Conference Call and Webcast to Review HBV Portfolio Progress

GlobeNewswire April 30, 2020

Research by Assembly Biosciences and Academic Collaborators Published in Hepatology Indicates cccDNA Turnover Time May Enable Hepatitis B Cures Following Finite Therapy

GlobeNewswire April 6, 2020

Assembly Biosciences Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 31, 2020

Assembly Biosciences Appoints Jason Okazaki as Chief Legal and Business Officer

GlobeNewswire March 30, 2020

Assembly Biosciences Reports Fourth Quarter and Year End 2019 Financial Results

GlobeNewswire March 4, 2020

Assembly Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 19, 2020

Assembly Biosciences Announces the Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

GlobeNewswire December 16, 2019

Assembly Biosciences Announces Pricing of $125 Million Public Offering

GlobeNewswire December 12, 2019

Assembly Biosciences Announces Proposed Public Offering of Common Stock

GlobeNewswire December 11, 2019

Assembly Biosciences Announces Plenary Lecture at HEP DART 2019

GlobeNewswire December 6, 2019

Assembly Biosciences Announces Presentation at Jefferies London Healthcare Conference

GlobeNewswire November 18, 2019